SEATTLE, WA / ACCESSWIRE / April 29, 2019 / I had the pleasure of sitting down with the founders of Pollination: Jagrit Pratap Singh, Pranav Rastogi and Muhammad Ali to discuss their business strategies and the world of digital marketing and internet technology at large.

For the uninitiated, Pollination is the powerhouse behind some of the hottest digital properties ranging from websites with millions of visitors to social media pages such as Art Studios, Take Moments, and Life Of A Rider, which have a combined following of millions of people. The company also owns and operates e-commerce businesses.

Being an Entrepreneur is Like Being a Parent

When asked about what motivates them and what drives them towards working towards their goals, Pranav replied:

Being an entrepreneur is a lot like being a parent. It’s not an easy job, it’s way too much taxing on your mental strength and you often doubt yourself whether you made the right choice or not. But in the end, it all seems so much worth it, when you see something you helped create achieve so much. This feeling. This is pretty much what drives us.

However, the biggest motivation at the end of the day is to see your business (your child) thrive and be successful. After a long day’s work, when you see the kind of impact your work has over millions of people across the world, it provides the greatest sense of satisfaction!

Talking Tech: Pollination’s Journey and the Future

Back when they started, Pranav recalls, they developed websites which often ranked in the top results on Google. The trio call those days as “the Digg-dot-com era.” However, after Digg’s impact waned away, they turned their focus towards social media and have since come up with huge pages “from the scratch,” Jagrit adds, which now have a collective following of over 15 Million people.

The three also tried their hand at viral marketing, resulting in the creation of Hiptoro – one of the most popular social media pages on Facebook. However Muhammad recalls a “humbling experience” when Facebook limited the audiences for Hiptoro after a crackdown on viral marketing pages. Following that, the three are now working on e-commerce business with NoahsCave, which they have already expanded in the US and Dubai, employing over 20 people.

Choose Your Friends Wisely

Reflecting over the past few years, Jagrit commented that they have met and worked with a lot of people over the years. Sceptics were always there. Then there were those who had too much belief upon them, hailing them to be “the next bill gates”. ‘A pedestal we didn’t deserve to be,’ he adds.

It is important to have people around you who are positive and optimistic – and believe in you. These people should also be practical. It is a rare combination to be pragmatic and optimistic at the same time, but when you find them – never let them go! Muhammad recalls that “We are glad to be in the company of good friends. Friends who never associated with us for any financial benefits or rewards but only out of the goodness of their heart. We are where we are thanks to them.”

CONTACT:

Hello@Pressline.com

SOURCE: Press Line

ReleaseID: 543413

Company to Expand Evaluation of Blockchain Technology in Life Sciences Product Development

CARLSBAD, CA / ACCESSWIRE / April 29, 2019 / Patriot Scientific Corporation (OTC PINK: PTSC) today is providing an update on its business plans.

Patriot Scientific Corporation is a public intellectual-property licensing company with several patents that are fundamental to modern microprocessor design. Chips licensing our technology cover the broad spectrum of the digital market and are used worldwide. From computers to cell phones, automobiles to entertainment systems, Patriot technology helps power your world.

Patriot’s business has been based on its experience with developing unique microprocessor architectured chips for which it began offering the core of its chip technology in the form of licensable intellectual property. Over time it became apparent that the company’s patented microprocessor technology was a standard setter for efficient low-cost, low-power design. The company has licensed its patents, collectively known as the Moore Microprocessor Patent (MMP) Portfolio™, through its joint-venture Phoenix Digital Solutions to over 100 companies.

While the company is continuing to defend its core technology through an ongoing patent appeal process, the company also recognizes that the future of the ongoing proceedings is uncertain. Given this uncertainty, the company is planning for its future by expanding its business initiatives into areas that build on its rich history in the high-tech area. The board and management have evaluated a number of potential areas for investment and have determined that the utilization of blockchain technology in life sciences product development represents an exciting area of opportunity.

“While we continue to pursue our interests in the Moore Microprocessor Patent Portfolio and evaluate the best path forward for potential future licensing and litigation, we also want to prepare for the future of the company. We have evaluated a number of potential areas for future investment and have identified the emerging area of blockchain in the life sciences area as an attractive area to pursue. Data security, integrity and auditability are core to the development of new drugs and the use of blockchain technology in this area is emerging as a potential solution,” stated Carlton Johnson, Patriot’s newly appointed Chief Executive Officer. “We believe there is an untapped opportunity to significantly improve the traditional drug development process through distributed ledger technology solutions, otherwise known as Blockchain, and believe blockchain technologies have the potential to be uniquely suited for creating efficiencies to improve how drugs are tested and developed, while ultimately leading to reduced costs. In order to continue our evaluation of opportunities in this area we have retained Artius Bioconsulting, LLC, in order to examine the potential for establishing a systems integration company focused on offering blockchain based solutions for pharmaceutical product development,” added Mr. Johnson.

Patriot plans to evaluate the use of blockchain based solutions in multiple areas of pharmaceutical product development including research and development, manufacturing, clinical trials and supply chain. The goal is to identify areas of opportunity that would provide technology solutions and real-world test cases in order to address current deficiencies throughout the drug development process.

“Our team has been evaluating the use of blockchain technology in the complex setting of drug development for some time now and we very much look forward to applying this knowledge base to help Patriot with their ongoing evaluation,” stated Steven King, President of Artius Bioconsultng. “There are inherent inefficiencies in the drug development process that span from research and development through the clinical trial process which can result in lost data and inefficiencies that can result in a significant increases in time and cost. The small percentage of drugs that reach approval bear the cumulative costs of process inefficiencies for both successful and failed drugs. Blockchain technology is potentially an attractive solution for addressing these inefficiencies,” added Mr. King.

About Patriot Scientific Corporation

Headquartered in Carlsbad, California, Patriot Scientific Corporation is the co-owner of the Moore Microprocessor Patent Portfolio. For more information on PTSC, visit www.ptsc.com.

About the MMP Portfolio™

The MMP Portfolio includes US patents as well as their European and Japanese counterparts, which cover techniques that enable higher performance and lower cost designs essential to consumer and commercial digital systems ranging from PCs, cell phones and portable music players to communications infrastructure, medical equipment and automobiles.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Patriot Scientific Corporation’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Patriot’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of emerging technologies and markets, raising sufficient capital to fund evaluation and implementation of new business initiatives, variations in Patriot’s cash flow, market acceptance risks, and technical development risks. Patriot’s business could be affected by a number of other factors, including the risk factors listed from time to time in Patriot’s SEC reports including, but not limited to, Patriot’s 10-K for the year ended May 31, 2018 filed with the SEC. Patriot cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Patriot disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

CONTACT:

Patriot Scientific Corp
760-795-8517

SOURCE: Patriot Scientific Corporation

ReleaseID: 543416

CASTLE ROCK, CO / ACCESSWIRE / April 29, 2019 / Riot Blockchain, Inc. (RIOT) (the ”Company”) announced today that, effective at 9:00 a.m., New York City time on April 29, 2019, the U.S. Securities Exchange Commission (the ”SEC”) declared effective the Registration Statement on Form S-3 (Number 333-230290), as amended (the ”Registration Statement”), filed by the Company for the resale of the common shares underlying the rights issued in connection with the January 28, 2019 convertible notes private placement first reported by the Company on February 1, 2019 (the ”Private Placement”). The Private Placement included, among other provisions, a requirement that the underlying common shares be registered for resale with the SEC and, with this notice of effectiveness, that requirement has been fulfilled. Any description of the Private Placement and the Company’s obligations thereunder in the foregoing is entirely qualified by reference to the exhibits to the Company’s current report on Form 8-K dated February 1, 2019, which, along with all of our SEC filings, is available at https://ir.riotblockchain.com/all-sec-filings.

This press release is not an offer to sell or exchange any securities of the Company, nor is it the solicitation of an offer to sell or exchange any securities of the Company. The Company will only offer to sell or exchange its securities to the public by filing a prospectus or prospectus supplement to the Registration Statement with the SEC.

About Riot Blockchain

Riot Blockchain is focused on building, operating, and supporting blockchain technologies. Its primary operations consist of cryptocurrency mining, targeted development of exchange platforms, along with other investments within the sector. For more information, visit: http://www.RiotBlockchain.com/.

Investor Notice

Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under “Risk Factors” in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2018 filed with the SEC on April 2, 2019, as amended by Amendment No. 1 on Form 10-K/A filed on April 23, 2019, as well as those risk factors disclosed in periodic and current reports we file with the SEC. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See “Safe Harbor” below.

Safe Harbor

The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic and current filings with the Securities and Exchange Commission, including the factors described in the sections entitled “Risk Factors”, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company does not undertake any obligation to update forward-looking statements contained in this press release.

Media Contact:

PR@RiotBlockchain.com

Investor Contact:

IR@RiotBlockchain.com

SOURCE: Riot Blockchain, Inc.

ReleaseID: 543411

NEW YORK, NY / ACCESSWIRE / April 29, 2019 / Bexil Corporation (OTC PINK:
BXLC) today reported its financial results for the first quarter ended March 31, 2019.

For the three months ended March 31, 2019, Bexil recorded net income attributable to Bexil shareholders of approximately $2.10 million or $2.40 per diluted share, compared to a net loss attributable to Bexil shareholders of approximately $0.90 million or $1.00 per diluted of loss per share for the three months ended March 31, 2018.

The Company’s book value per share attributable to Bexil shareholders at March 31, 2019 was $23.26, based on shareholders’ equity attributable to Bexil shareholders of approximately $20.2 million and 867,728 shares issued and outstanding.

The Company’s unaudited balance sheet, statements of comprehensive income, and statements of cash flows as of and for the three months ended March 31, 2019 are appended to the copy of this press release on www.Bexil.com.

About Bexil Corporation

Bexil is primarily engaged through a subsidiary in investment management. To learn more about Bexil, including Rule 15c2-11 information, please visit www.Bexil.com.

Safe Harbor Note

This release contains certain “forward looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Bexil, which may cause the Company’s actual results to be materially different from those expressed or implied by such statements. Investors should carefully consider the risks, uncertainties and other factors, together with all of the other information included in the Company’s Annual Report, at http://www.bexil.com/cautionary-language.html, and similar information. The forward looking statements made herein are only made as of the date of this release, and the Company undertakes no obligation to publicly update such forward looking statements to reflect subsequent events or circumstances.

The Company views book value per share, a non-GAAP financial measure, as an important indicator of financial performance. Presented in conjunction with other financial information, the combined presentation can enhance an investor’s understanding of the Company’s underlying financial condition and results from operations. The definition of book value as presented in this press release is shareholders’ equity attributable to Bexil shareholders divided by currently issued and outstanding shares.

Contact:

Thomas O’Malley
Chief Financial Officer
1-212-785-0900
tomalley@bexil.com
www.Bexil.com

SOURCE: Bexil Corporation

ReleaseID: 543399

NEW YORK, NY / ACCESSWIRE / April 29, 2019 / Bexil Corporation (OTC PINK: BXLC) today reported its financial results for the year ended December 31, 2018. Bexil recorded a net loss attributable to Bexil shareholders of $1.27 million or $1.43 per diluted share for the year ended December 31, 2018, compared to net income attributable to Bexil shareholders of $1.90 million or $2.02 per diluted share for the year ended December 31, 2017.

The Company’s book value per share attributable to Bexil shareholders at December 31, 2018 was $20.77, based on shareholders’ equity attributable to Bexil shareholders of approximately $18.0 million and 867,728 shares issued and outstanding, a per share decrease of 5.0% from $21.96 per share a year earlier.

2019 Annual Meeting of Stockholders

Bexil’s 2019 annual meeting of stockholders will be held at 11 Hanover Square, 12th Floor, New York, New York on June 5, 2019 at 11:30 a.m., local time. Stockholders of record at the close of business on April 30, 2019 are entitled to receive notice of and to vote at the meeting. After the formal business of the meeting is concluded, company executives will make a presentation of financial results and business developments and respond to questions. To access the annual meeting and presentation by conference call, please dial 1-267-930-4000, Access Code: 373-498-588#.

The Company’s combined Notice of 2019 Annual Meeting and Proxy Statement and 2018 Annual Report, including audited financial statements, is available on www.Bexil.com.

About Bexil Corporation

Bexil is primarily engaged through a subsidiary in investment management. To learn more about Bexil, including Rule 15c2-11 information, please visit www.Bexil.com.

Safe Harbor Note

This release contains certain ”forward looking statements” made pursuant to the ”safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Bexil, which may cause the Company’s actual results to be materially different from those expressed or implied by such statements. Investors should carefully consider the risks, uncertainties and other factors, together with all of the other information included in the Company’s Annual Report, at http://www.bexil.com/cautionary-language.html, and similar information. The forward looking statements made herein are only made as of the date of this release, and the Company undertakes no obligation to publicly update such forward looking statements to reflect subsequent events or circumstances.

The Company views book value per share, a non-GAAP financial measure, as an important indicator of financial performance. Presented in conjunction with other financial information, the combined presentation can enhance an investor’s understanding of the Company’s underlying financial condition and results from operations. The definition of book value as presented in this press release is shareholders’ equity attributable to Bexil shareholders divided by currently issued and outstanding shares.

Contact:

Thomas O’Malley
Chief Financial Officer
1-212-785-0900
tomalley@bexil.com
www.Bexil.com

SOURCE: Bexil Corporation

ReleaseID: 543400

PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / April 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced today that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. I-Mab has exclusive rights for development and commercialization of MOR202/TJ202 in China, Taiwan, Hong Kong and Macao.

“The initiation of our first phase 3 trial represents another important milestone in advancing MOR202/TJ202 towards registration with the hope of providing more therapeutic options for multiple myeloma patients globally. With planned enrollment of 291 patients, this will be a broad trial of this second most common blood cancer worldwide,” said Dr. Joan Shen, M.D., Head of R&D at I-Mab. “In parallel with our pivotal phase 2 trial of MOR202/TJ202 in combination with dexamethasone, the phase 3 study will further assess the efficacy of MOR202/TJ202 as a potential second line treatment in multiple myeloma.”

Under I-Mab’s fast-to-market development strategy, the phase 3 study, if successful, could lead to a biologics license application (BLA) in Greater China. The randomized, open-label, parallel-controlled, multicenter study will be conducted in mainland China and Taiwan to evaluate the efficacy and safety of the combination of MOR202/TJ202 plus lenalidomide (LEN) and dexamethasone (DEX) versus the combination of LEN and DEX in patients with relapsed or refractory multiple myeloma who received at least one prior line of treatment. The primary endpoint is to evaluate the progression-free survival (PFS) comparing the efficacy of MOR202/TJ202 plus LEN/DEX versus LEN/DEX.

The dosing of the first patient triggers a milestone payment of USD 3 million to MorphoSys.

“We are delighted that our partner I-Mab has started a phase 3 trial of MOR202/TJ202 in combination with lenalidomide in Asia in addition to the ongoing phase 2 trial of MOR202 in combination with dexamethasone. We see a high medical need for the treatment of patients with multiple myeloma in the Chinese region and look forward to supporting I-Mab in developing this investigational compound for these patients,” said Dr. Malte Peters, Chief Development Officer of MorphoSys AG.

With MorphoSys’s support through a licensing agreement in November 2017, I-Mab is currently leading the clinical development of MOR202/TJ202 in Greater China, including mainland China, Hong Kong, Macao and Taiwan. In addition to Taiwan, I-Mab has filed an investigational new drug (IND) application to China’s National Medical Products Administration in August 2018. Previously on March 20, 2019, MorphoSys and I-Mab announced the first patient dosing of MOR202/TJ202 in a phase 2 multi-center clinical study in Taiwan in patients with relapsed or refractory multiple myeloma.

About MOR202/TJ202

MOR202/TJ202 is an investigational human monoclonal antibody derived from MorphoSys’s HuCAL antibody technology. The antibody is directed against CD38 on the surface of multiple myeloma cells, which has been characterized as one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells. According to its suggested mode of action, the antibody recruits cells of the body’s immune system to kill the tumor through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The antibody does not involve complement dependent cytotoxicity, or CDC, an additional immune mechanism involved in tumor cell killing. Scientific research suggest that an anti-CD38 antibody may have therapeutic potential also in other cancers as well as autoimmune diseases. Based on an exclusive regional licensing agreement signed in late 2017, I-Mab owns the exclusive rights for development and commercialization of MOR202/TJ202 in China, Taiwan, Hong Kong and Macao.

About I-Mab Biopharma

I-Mab is a dynamic and fast-growing global player exclusively focused on developing first-in-class and best-in-class biologics in the areas of immuno-oncology and autoimmune diseases through internal R&D capabilities and global partnerships. I-Mab’s pipeline is driven by the company’s development strategy to address unmet needs in China and to bring innovative assets to the world. According to I-Mab, the company is prepared to submit additional INDs in order to initiate clinical trials in China and the U.S., including multiple Phase 2 and Phase 3 studies. I-Mab states to be on a fast track toward becoming an end-to-end fully integrated biopharma company. The company has been well-recognized by capital markets by successfully raising approximately USD 370 million within 12 months, with the recent USD 220 million Series C financing which represents one of the largest amounts ever raised by an innovative biotech company in China, as stated by I-Mab. www.i-mabbiopharma.com.

About MorphoSys:

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys’s antibody technology to receive regulatory approval. The Company’s most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 330 employees. More information at https://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

MorphoSys’s forward looking statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including expectations regarding the initiation of a phase 3 clinical study to evaluate MorphoSys’s investigational CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma in Taiwan as well as the size and scope of this study, expectations in connection with MOR202/TJ202 and expectations regarding the further development of MOR202/TJ202 in multiple myeloma in Greater China, including the intended targeting of CD38 and the suggested mode of action, potential additional indications such as autoimmune diseases, as well as expectations regarding a potential future regulatory fling for MOR202/TJ202 and expectations around the submission of an IND application to China’s National Medical Products Administration for MOR202/TJ202. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys’ results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys’s expectations regarding the initiation of a phase 2 clinical study to evaluate MorphoSys’s investigational CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma in Taiwan as well as the size and scope of this study, expectations in connection with MOR202/TJ202 and expectations regarding the further development of MOR202/TJ202 in multiple myeloma in Greater China, including the intended targeting of CD38 and the suggested mode of action, potential additional indications such as autoimmune diseases, as well as expectations regarding a potential future regulatory fling for MOR202/TJ202 and expectations around the submission of an IND application to China’s National Medical Products Administration for MOR202/TJ202 are false, MorphoSys’s reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys’s Registration Statement on Form F-1 and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

MorphoSys AG
Dr. Sarah Fakih
Head of Corporate Communications &IR

Alexandra Goller
Director Corporate Communications & IR

Dr. Julia Neugebauer
Director Corporate Communications & IR

Dr. Verena Kupas
Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
I-Mab Biopharma
Raven Lin
Vice President of Corporate Development
raven.lin@i-mabbiopharma.com

Jielun Zhu
CFO
jielun.zhu@i-mabbiopharma.com

Amanda Dai
Associate Director of Public Relation
zhehua.dai@i-mabbiopharma.com

SOURCE: MorphoSys AG

ReleaseID: 543397